Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with these underlying malignancies will be eligible for this study: Autologous BMT patients, Allogeneic BMT patients, and patients with hematological malignancy.~2. Patients must be at least 5 years of age.~3. Only patients with infection limited to the URT will be eligible for entry on study~4. Patients will be eligible for entry on study if a nasopharyngeal wash or throat swab specimen is positive by rapid RSV antigen testing or by a positive culture for RSV.~Exclusion Criteria:~1. Patients with evidence of RSV LRTI as documented by a positive rapid RSV antigen testing or by a positive culture for RSV from a nasopharyngeal wash or throat swab AND new infiltrates on chest radiograph and/or abnormal blood gas determination~2. Patients with hypersensitivity to ribavirin or its components~3. Pregnant women. Participants must practice birth control during the study if they are sexually active. If the participant is pregnant, she may not be enrolled on this study. Mothers should refrain from breast-feeding during the study to avoid injury to their children.~4. Patients with positive RSV by rapid testing or culture in bronchoalveolar lavage regardless of the chest radiographic results.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Standard Schedule - Ribavirin (Type: EXPERIMENTAL): Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
- 2: Modified Schedule - Ribavirin (Type: EXPERIMENTAL): Aerosolized Ribavirin 2 grams over 3 hours every 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).